BCHE and Alzheimer disease: The traditional landscape of treatment options for AD consists of currently EC-listed cholinesterase inhibitors (ChEIs) for patients with mild to moderate disease (with the exception of donepezil, which is also approved for moderate to severe disease), and the N-methyl-D-aspartate (NMDA) receptor partial antagonist memantine approved for use in moderate to severe AD [36].